苯磺酸氨氯地平联合缬沙坦对高血压患者血压控制及血清ET-1水平的影响

侯大毅

【摘要】 目的：探討苯磺酸氨氯地平+缬沙坦对高血压患者血压控制及血清内皮素-1（ET-1）水平的影响。方法：选取笔者所在医院2018年1月-2019年1月收治的高血压患者120例，随机分成两组，每组60例。对照组采用苯磺酸氨氯地平治疗，观察组采用苯磺酸氨氯地平+缬沙坦联合治疗，两组均连续治疗2个月。比较两组治疗前后血压、心率、血清ET-1、空腹血糖、血脂（总胆固醇、甘油三酯）、肾功能（血肌酐、尿素氮）、肝功能（总胆红素）变化情况、治疗总有效率及不良反应发生率。结果：治疗后两组血压、血清ET-1水平均较治疗前明显降低（P<0.05）;观察组治疗后血压、血清ET-1水平均低于对照组（P<0.05）;两组治疗前后心率比较，差异均无统计学意义（P>0.05）;观察组治疗总有效率高于对照组（P<0.05）;两组治疗前后空腹血糖、血脂、肝肾功能比较，差异均无统计学意义（P>0.05）;观察组不良反应发生率低于对照组（P<0.05）。结论：苯磺酸氨氯地平+缬沙坦能更好地控制高血压患者的血压，降低血清ET-1水平，疗效显著，安全性高。

【关键词】 高血压 苯磺酸氨氯地平 缬沙坦 血压控制 血清ET-1

doi：10.14033/j.cnki.cfmr.2019.29.006 文献标识码 A 文章编号 1674-6805（2019）29-00-03

[Abstract] Objective： To investigate the effects of Amlodipine Besylate combined with Valsartan on blood pressure control and serum endothelin-1 （ET-1） levels in patients with hypertension. Method： A total of 120 patients with hypertension who were admitted to the hospital from January 2018 to January 2019 were enrolled. They were randomly divided into two groups， 60 cases in each group. The control group was given Amlodipine Besylate， while the observation group was given Amlodipine Besylate combined with Valsartan. Both groups were treated continuously for 2 months. The changes of blood pressure， heart rate， serum ET-1， fasting blood glucose， blood lipids （total cholesterol， triglycerides）， renal function （serum creatinine， urea nitrogen）， liver function （total bilirubin）， and total effective rate and incidence of adverse reactions were compared between the two groups. Result： After treatment， blood pressure and serum ET-1 levels of the two groups were significantly lower than those before treatment （P<0.05）. After treatment， blood pressure and serum ET-1 levels in the observation group were lower than those of the control group （P<0.05）. Heart rates of the two groups were compared before and after treatment， and the differences were not statistically significant （P>0.05）. The total effective rate of treatment in the observation group was higher than that of the control group （P<0.05）. Fasting blood glucose， blood lipid， liver and renal function were compared between the two groups before and after treatment， and the differences were not statistically significant （P>0.05）. The incidence of adverse reactions in the observation group was lower than that of the control group （P<0.05）. Conclusion： Amlodipine Besylate combined with Valsartan can well control blood pressure of patients with hypertension， and reduce serum ET-1 level， with significant curative effect and high safety.

[Key words] Hypertension Amlodipine Besylate Valsartan Blood pressure control Serum ET-1

First-authors address： Xishui County Traditional Chinese Medicine Hospital， Xishui 438200， China

随着人们经济水平的提高和生活压力的增大，高血压的发病率越来越高，成为临床中常见疾病[1]。据调查结果显示，我国18岁以上人群的高血压患病率为27.9%[2]。高血压是脑卒中、冠心病等疾病发病和死亡的主要原因之一，致残致死率高，预后差[3-4]。因此，寻找针对高血压安全有效的治疗方法至关重要。目前，高血压的治疗方法主要为药物治疗，包括β受体阻滞剂、血管紧张素转换酶抑制剂、钙通道阻滞剂等，药物作用机制均比较明确，在临床上已广泛运用。但传统的降压治疗往往都是单一用药，治疗效果一般。现阶段，临床主张两种或两种以上药物联合使用，使药物间优势互补，减少用药剂量，减轻不良反应，发挥最佳药效[5]。……